Aripiprazole
Product Images NDC 17856-0570

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (17856 0570 01)

Aripiprazole Oral Solution is delivered at 5mg/5mL per cup. Dosage and indications are available in the package insert. Store the solution at room temperature, keeping it away from the children. The solution comes in a quantity of 72 cups and has an expiration date of 12109120. The product is distributed by AtlanticBiologicals Corp, Miami. To reorder, call 800.509.7592.*

FDA Label Image

17856 0570 02

This is a description of Aripiprazole Oral solution delivered at a concentration of 5mg/ml. The package insert indicates the indications and dosage schedule. The solution needs to be stored at controlled room temperature within 15-30°C (59-86°F), and kept away from children. The dosage is 5ml (17856-0570-02). This solution is manufactured by Unit Dose Solutions, distributed by Atlantic Biologicals Corp., and have a SIN of 01333301 RX, and GTIN of 0011785607024. The expiry date of the product is 09/12/21. Call 800.509.7592 for reorder.*

FDA Label Image

Structure (Aripiprazole Oral Solution 1)

FDA Label Image

Figure 1 (Aripiprazole Oral Solution 2)

This appears to be a figure caption from a research article showing the effects of other drugs on the pharmacokinetics of aripiprazole. The image seems to illustrate the change in relative bioavailability and maximum concentration caused by co-administration of different drugs. It is not possible to obtain a clear understanding of the entire analysis from this caption only.*

FDA Label Image

Figure 2 (Aripiprazole Oral Solution 3)

This appears to be a figure with the title "The effects of other drugs on dehydro-aripiprazole pharmacokinetics" and its content shows the impact of different drugs on Aripiprazole. The graph shows changes relative to the reference without an interacting drug and displays the effect on different parameters like Cmax and AUC. No detailed information is available.*

FDA Label Image

Figure 3 (Aripiprazole Oral Solution 4)

This text describes the effects of Aripiprazole on the pharmacokinetics of other drugs. Figure 3 is provided, which represents the relative change in the pharmacokinetics of different drugs when taking Aripiprazole compared to a reference state without taking any drugs. The scientific data table includes the names of the drugs and the changes in their effect while taking Aripiprazole.*

FDA Label Image

Figure 4 (Aripiprazole Oral Solution 5)

The given text contains a table or a figure named "Figure 4" that represents the effects of intrinsic factors on aripiprazole pharmacokinetics for special populations. The table presents changes in AUC R based on intrinsic factors such as poor vs. extensive metabolizers, gender, weight, hepatic impairment (normal vs. moderate vs. severe), and renal impairment (severe). Apart from this, no other information is available in the given text, so the description is not comprehensive enough to convey a meaningful understanding of the topic.*

FDA Label Image

Figure 5 (Aripiprazole Oral Solution 6)

FDA Label Image

Figure 6 (Aripiprazole Oral Solution 7)

FDA Label Image

Figure 7 (Aripiprazole Oral Solution 8)

FDA Label Image

Figure 8 (Aripiprazole Oral Solution 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.